Citations

Clear

33 citation(s) found for "Toft, D O".

Phase I study of CNF1010 (lipid formulation of 17-(allylamino)-17-demethoxygeldanamycin: 17-AAG) in patients with advanced solid tumors
Saif, M. W. , Erlichman, Charles , Mendelson, David S. , Toft, D., Timony, G., Burrows, F., Padgett, C., Jager, R. De, Hoff, D. Von, Dragovich, Tomislav , Toft, D., Timony, G., Burrows, F., Padgett, C., Jager, R. De, Hoff, D. Von

Mayo Clinic

Journal of Clinical Oncology | March 9, 2020 | Volume: 24 | Issue: 18_suppl | Pages: 10062-10062

10.1200/jco.2006.24.18_suppl.10062 Get It

10062 Background: 17-AAG is a benzoquinone ansamycin that binds to and inhibits the HSP90 family of molecular chaperones leading to the proteasomal degradation of client proteins critical in malignant cell proliferation and survival. We have undertaken a Phase 1 trial of CNF1010, an oil-in-water nanoemulsion of 17-AAG. Methods: Patients (pts) with advanced solid tumors, ECOG PS 0–2, and adequate hematologic, hepatic, renal and cardiac functions received CNF1010 by 1 h intravenous infusion, twice-a-week, three weeks out of four, starting at 6 mg/m2 per dose. Doses were escalated sequentially in single pts (6 and 12 mg/m2) and 3–6 pts (≥ 25 mg/m2) cohorts according to a modified Fibonacci’s schema. Plasma pharmacokinetic (PK) profiles were obtained on days 1 and 18. Biomarkers were measured in PBMC’s (HSP70) and plasma (HER-2 ectodomain (HER-2 ECD)). Results: 30 pts (M/F: 14/16; median age 63, range 48–78) with colorectal cancer (11), pancreatic cancer (5), melanoma (5), ovarian (2), others (7) were treated with a median of 2 courses (range: 1–10). There was no dose-limiting toxicity up to 175 mg/m2. One pt at 175 mg/m2 died on study, but drug relation was unclear. Grade 1–2 gastrointestinal toxicities (nausea, vomiting, diarrhea) and serum creatinine elevation were observed. Severe toxicities (grade 3 but no grade 4) consisted of reversible hepatic enzyme elevation, hyperbilirubinemia, fatigue, anemia and hyperglycemia. There were no hematological toxicities. Plasma 17-AAG PK appeared dose-proportional (AUC, Cmax); CL (17 L/h/m2) and t1/2 (5.2 h) were dose independent and unchanged after repeated dosing (day 18). Post-treatment increases in HSP70 were observed in PBMCs and decreases in plasma HER-2 ECD were observed at doses ≥ 83 mg/m2. Minor tumor regressions were seen in 1 pt with duodenal cancer (83 mg/m2), 1 pt with gastric carcinoid (175 mg/m2) and 1 pt with melanoma (175 mg/m2). Conclusion: The threshold of biologic activity for CNF1010 administered by a twice a week schedule appears to be 83 mg/m2. This dosing regimen appears to be optimal and supported by the pharmacokinetic and pharmacodynamic data. The MTD has not yet been determined. Dose escalation of CNF1010 continues at 225 mg/m2. [Table: see text]
Fine‐Mapping of SNCA in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies
Krohn, Lynne , Wu, Richard Y. J. , Heilbron, Karl , Ruskey, Jennifer A. , Laurent, Sandra B., Blauwendraat, Cornelis , Alam, Armaghan , Arnulf, Isabelle , Hu, Michele T.M., Dauvilliers, Yves , Högl, Birgit , Toft, Mathias , Bjørnarå, Kari Anne , Stefani, Ambra , Holzknecht, Evi , Monaca, Christelle, Abril, Beatriz, Young, Peter , Heidbreder, Anna , Mollenhauer, Brit , Sixel‐Döring, Friederike , Trenkwalder, Claudia , Šonka, Karel , Figorilli, Michela , Puligheddu, Monica , Dijkstra, Femke , Viaene, Mineke , Oertel, Wolfang, Toffoli, Marco , Gagnon, Jean‐François , Nalls, Mike A., Singleton, Andrew B., Désautels, Alex , Montplaisir, Jacques , Ross, Owen A. , Dupré, Nicolas , Postuma, Ronald B., Antelmi, Elena , Cochen De Cock, Valérie , Rouleau, Guy Armand , Gan-Or, Ziv , Ross, Owen A , Dauvilliers, Yves , Stefani, Ambra , Toft, Mathias , Arnulf, Isabelle , Högl, Birgit , Sonka, Karel , Figorilli, Michela , Puligheddu, Monica , Heidbreder, Anna , Plazzi, Giuseppe , Antelmi, Elena , Ferini-Strambi, Luigi , Kemlink, David , Gigli, Gian Luigi , Valente, Mariarosaria , Singleton, Andrew , Cannon, Paul, Boeve, Bradley F. , Fon, Edward A , Postuma, Ronald B. , Pihlstrøm, Lasse , Gan‐Or, Ziv

Mayo Clinic

Annals of Neurology | January 24, 2020 | Volume: 87 | Issue: 4 | Pages: 584-598

10.1002/ana.25687 | PMID 31976583 Get It

Objective Rapid eye movement sleep behavior disorder (RBD) is a prodromal synucleinopathy, as >80% will eventually convert to overt synucleinopathy. We performed an in‐depth analysis of the SNCA locus to identify RBD‐specific risk variants. Methods Full sequencing and genotyping of SNCA was performed in isolated/idiopathic RBD (iRBD, n = 1,076), Parkinson disease (PD, n = 1,013), dementia with Lewy bodies (DLB, n = 415), and control subjects (n = 6,155). The iRBD cases were diagnosed with RBD prior to neurodegeneration, although some have since converted. A replication cohort from 23andMe of PD patients with probable RBD (pRBD) was also analyzed (n = 1,782 cases; n = 131,250 controls). Adjusted logistic regression models and meta‐analyses were performed. Effects on conversion rate were analyzed in 432 RBD patients with available data using Kaplan–Meier survival analysis. Results A 5′‐region SNCA variant (rs10005233) was associated with iRBD (odds ratio [OR] = 1.43, p = 1.1E‐08), which was replicated in pRBD. This variant is in linkage disequilibrium (LD) with other 5′ risk variants across the different synucleinopathies. An independent iRBD‐specific suggestive association (rs11732740) was detected at the 3′ of SNCA (OR = 1.32, p = 4.7E‐04, not statistically significant after Bonferroni correction). Homozygous carriers of both iRBD‐specific SNPs were at highly increased risk for iRBD (OR = 5.74, p = 2E‐06). The known top PD‐associated variant (3′ variant rs356182) had an opposite direction of effect in iRBD compared to PD. Interpretation There is a distinct pattern of association at the SNCA locus in RBD as compared to PD, with an opposite direction of effect at the 3′ of SNCA . Several 5′ SNCA variants are associated with iRBD and with pRBD in overt synucleinopathies. ANN NEUROL 2020;87:584–598
Influence of Acetylsalicylic Acid Use on Risk and Outcome of Community-Acquired Staphylococcus aureus Bacteremia: A Population-Based Study
Smit, Jesper, Dalager‐Pedersen, Michael , Kaasch, Achim J. , Thomsen, Reimar W. , Frøslev, Trine , Nielsen, Henrik , Schønheyder, Henrik Carl , Sørensen, Henrik Toft , Søgaard, Mette , Adelborg, Kasper , DeSimone, Christopher V. , DeSimone, Daniel C.

Mayo Clinic

Open Forum Infectious Diseases | September 20, 2019 | Volume: 6 | Issue: 9 | Pages: No page available

10.1093/ofid/ofz356 | PMID 31660413 Get It

Abstract Objective To investigate the influence of acetylsalicylic acid (ASA) use on risk and outcome of community-acquired Staphylococcus aureus bacteremia (CA-SAB). Method We used population-based medical databases to identify all patients diagnosed in northern Denmark with first-time CA-SAB and matched population controls from 2000–2011. Categories for ASA users included current users (new or long-term users), former users, and nonusers. The analyses were adjusted for comorbidities, comedication use, and socioeconomic indicators. Results We identified 2638 patients with first-time CA-SAB and 26 379 matched population controls. Compared with nonusers, the adjusted odds ratio (aOR) for CA-SAB was 1.00 (95% confidence interval [CI], 0.88–1.13) for current users, 1.00 (95% CI, 0.86–1.16) for former users, 2.04 (95% CI, 1.42–2.94) for new users, and 0.95 (95% CI, 0.84–1.09) for long-term users. Thirty-day cumulative mortality was 28.0% among current users compared with 21.6% among nonusers, yielding an adjusted hazard rate ratio (aHRR) of 1.02 (95% CI, 0.84–1.25). Compared with nonusers, the aHRR was 1.10 (95% CI, 0.87–1.40) for former users, 0.60 (95% CI, 0.29–1.21) for new users, and 1.06 (95% CI, 0.87–1.31) for long-term users. We observed no difference in the risk or outcome of CA-SAB with increasing ASA dose or by presence of diseases commonly treated with ASA. Conclusions Use of ASA did not seem to influence the risk or outcome of CA-SAB. The apparent increased risk among new users may relate to residual confounding from the circumstances underlying ASA treatment initiation. Our finding of no association remained robust with increasing ASA dose and across multiple patient subsets.
A phase I trial of gemcitabine (Gem), 17-allylaminogeldanamycin (17-AAG) and cisplatin (CDDP) in solid tumor patients
Toft, D O, Steinmetz, Susan , Furth, Alfred, Mandrekar, Sumithra J. , Stensgard, Bridget, McCollum, Andrea K., Hanson, L., Adjei, Alex A. , Erlichman, Charles , Haluska, Paul

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 3058-3058

10.1200/jco.2004.22.90140.3058 Get It

A phase I trial of 17-allylamino-geldanamycin (17AAG) in patients with advanced cancer
Erlichman, Charles , Toft, D O, Reid, J., Ames, M. M., Mandrekar, Sumithra J. , Ajei, A., McCollum, Andrea K., Ivy, Percy, Goetz, Matthew P.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 3030-3030

10.1200/jco.2004.22.90140.3030 Get It

Exome Variant Mining in Familial Parkinson Disease
Toft, Mathias , Ross, Owen A. , Ross, Owen A , Toft, Mathias

Mayo Clinic

JAMA Neurology | November 23, 2015 | Volume: 73 | Issue: 1 | Pages: 21

10.1001/jamaneurol.2015.3536 | PMID 26595415 Get It

FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells
Yang, Chunsong , Gioeli, Daniel , Frierson, Henry F., Toft, David O., Paschal, Bryce M. , Li, Ni

Mayo Clinic

Molecular and Cellular Biology | January 4, 2010 | Volume: 30 | Issue: 5 | Pages: 1243-1253

10.1128/mcb.01891-08 | PMID 20048054 Get It

Cisplatin abrogates the geldanamycin-induced heat shock response
McCollum, Andrea K., Lukasiewicz, Kara B., TenEyck, Cynthia J., Lingle, Wilma L., Toft, David O., Erlichman, Charles

Mayo Clinic

Molecular Cancer Therapeutics | October 13, 2008 | Volume: 7 | Issue: 10 | Pages: 3256-3264

10.1158/1535-7163.mct-08-0157 | PMID 18852129 Get It

Abstract Benzoquinone ansamycin antibiotics such as geldanamycin (GA) bind to the NH2-terminal ATP-binding domain of heat shock protein (Hsp) 90 and inhibit its chaperone functions. Despite in vitro and in vivo studies indicating promising antitumor activity, derivatives of GA, including 17-allylaminogeldanamycin (17-AAG), have shown little clinical efficacy as single agents. Thus, combination studies of 17-AAG and several cancer chemotherapeutics, including cisplatin (CDDP), have begun. In colony-forming assays, the combination of CDDP and GA or 17-AAG was synergistic and caused increased apoptosis compared with each agent alone. One measurable response that results from treatment with Hsp90-targeted agents is the induction of a heat shock factor-1 (HSF-1) heat shock response. Treatment with GA + CDDP revealed that CDDP suppresses up-regulation of HSF-1 transcription, causing decreased levels of stress-inducible proteins such as Hsp27 and Hsp70. However, CDDP treatment did not prevent trimerization and nuclear localization of HSF-1 but inhibited DNA binding of HSF-1 as shown by chromatin immunoprecipitation. Melphalan, but not camptothecin, caused similar inhibition of GA-induced HSF-1–mediated Hsp70 up-regulation. 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt cell survival assays revealed that deletion of Hsp70 caused increased sensitivity to GA (Hsp70+/+ IC50 = 63.7 ± 14.9 nmol/L and Hsp70−/− IC50 = 4.3 ± 2.9 nmol/L), which confirmed that a stress response plays a critical role in decreasing GA sensitivity. Our results suggest that the synergy of GA + CDDP is due, in part, to CDDP-mediated abrogation of the heat shock response through inhibition of HSF-1 activity. Clinical modulation of the HSF-1–mediated heat shock response may enhance the efficacy of Hsp90-directed therapy. [Mol Cancer Ther 2008;7(10):3256–64]
P-Glycoprotein–Mediated Resistance to Hsp90-Directed Therapy Is Eclipsed by the Heat Shock Response
McCollum, Andrea K., TenEyck, Cynthia J., Stensgard, Bridget, Morlan, Bruce W., Jenkins, Robert B. , Toft, David O., Erlichman, Charles , Ballman, Karla V.

Mayo Clinic

Cancer Research | September 15, 2008 | Volume: 68 | Issue: 18 | Pages: 7419-7427

10.1158/0008-5472.can-07-5175 | PMID 18794130 Get It

Abstract Despite studies that show the antitumor activity of Hsp90 inhibitors, such as geldanamycin (GA) and its derivative 17-allylamino-demethoxygeldanamycin (17-AAG), recent reports indicate that these inhibitors lack significant single-agent clinical activity. Resistance to Hsp90 inhibitors has been previously linked to expression of P-glycoprotein (P-gp) and the multidrug resistant (MDR) phenotype. However, the stress response induced by GA treatment can also cause resistance to Hsp90-targeted therapy. Therefore, we chose to further investigate the relative importance of P-gp and the stress response in 17-AAG resistance. Colony-forming assays revealed that high expression of P-gp could increase the 17-AAG IC50 6-fold in cells transfected with P-gp compared with parent cells. A549 cells selected for resistance to GA overexpressed P-gp, but verapamil did not reverse the resistance. These cells also overexpressed Hsp27, and Hsp70 was induced with 17-AAG treatment. When the GA and 17-AAG resistant cells were transfected with Hsp27 and/or Hsp70 small interfering RNA (siRNA), the 17-AAG IC50 decreased 10-fold compared with control transfected cells. Transfection with siRNA directed against Hsp27, Hsp70, or Hsp27 and Hsp70 also increased sensitivity to EC78, a purine scaffold-based Hsp90 inhibitor that is not a P-gp substrate. We conclude that P-gp may contribute, in part, to resistance to 17-AAG, but induction of stress response proteins, such as Hsp27 and Hsp70, by Hsp90-targeted therapy plays a larger role. Taken together, our results indicate that targeting of Hsp27 and Hsp70 should be exploited to increase the clinical efficacy of Hsp90-directed therapy. [Cancer Res 2008;68(18):7419–27]
Role of the Cochaperone Tpr2 in Hsp90 Chaperoning
Moffatt, Nela, Bruinsma, Elizabeth S. , Uhl, Cindy B., Obermann, Wolfgang M.J. , Toft, David O.

Mayo Clinic

Biochemistry | July 12, 2008 | Volume: 47 | Issue: 31 | Pages: 8203-8213

10.1021/bi800770g | PMID 18620420 Get It